ONCE AGAIN, THE COMBINATION of the pandemic and the federal government may be creating a credible new competitor in the in vitro diagnostics (IVD) industry. This time, the lucky company is Ellume, which was just awarded $231.8 million from the Biden administration to scale up production of a home test for SARS-CoV-2. Ellume was given an emergency-use authorization (EUA) from the federal Food and […]
- Lab Market Update
Critics Say New At-Home Test Is Expensive and Late to Market
They say the first over-the-counter test for COVID-19 to get EUA status from the FDA “is a waste of money”
- By Robert Michel
- > From the Volume XXVIII, No. 2 - February 8, 2021 Issue
